Menu

Featured

News
Media
Awards
Contact
News
Media Resources
Awards
Contact
February 7, 2023
Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies

2026

2025

2024

2023

2022

2021

2020

2019

August 30, 2022
Asieris Included in the SSE STAR Biology and Medicine Index
April 17, 2026
Asieris Pharmaceuticals Releases 2025 Annual Report：Flagship Product Approval Marks Inflection Point; Commercialization 2.0 Drives Growth
February 7, 2023
Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies
August 30, 2022
Asieris Included in the SSE STAR Biology and Medicine Index
March 3, 2026
Asieris’ CEVIRA® Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions
February 7, 2023
Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies
August 30, 2022
Asieris Included in the SSE STAR Biology and Medicine Index
January 8, 2026
Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors
February 7, 2023
Asieris and ReviR Enter into Research Collaboration Agreement to Discover Oncology Therapeutics Based on ReviR’s Comprehensive Approach to RNA-targeting Technologies